Two competing approaches to predicting heart disease risk have dominated clinical practice on opposite sides of the Atlantic, creating uncertainty about which method delivers more reliable guidance for prevention strategies. This massive validation effort across 6.4 million individuals in 44 observational studies and 18 randomized trials provides the first comprehensive head-to-head comparison of America's PREVENT calculator against Europe's SCORE2 system. Both risk assessment tools demonstrated remarkably similar predictive accuracy when tested across diverse geographical regions and populations, suggesting that the choice between systems may matter less than previously assumed. The analysis found generally robust performance for both calculators in estimating 10-year cardiovascular event probability, with neither showing clear superiority in identifying high-risk individuals who would benefit most from preventive interventions like statins or lifestyle modifications. This convergence represents a significant advance for personalized cardiovascular medicine, as it validates that clinicians on both continents are working with fundamentally sound risk stratification frameworks. The findings also suggest that global harmonization of risk assessment approaches may be more feasible than anticipated, potentially simplifying clinical guidelines and reducing confusion when patients move between healthcare systems. However, the study's observational design cannot definitively establish whether using these risk scores actually improves patient outcomes compared to clinical judgment alone. The real-world impact depends on how effectively healthcare providers integrate these tools into shared decision-making conversations and translate risk estimates into actionable prevention plans that patients will actually follow.